Eva Pharma Sustainability Profile
Eva Pharma, a leading pharmaceutical company headquartered in Egypt, has established itself as a key player in the healthcare industry since its founding in 1997. With a strong presence across the Middle East and North Africa, the company focuses on developing, manufacturing, and marketing a diverse range of innovative medicines and healthcare solutions. Specialising in therapeutic areas such as oncology, cardiology, and infectious diseases, Eva Pharma is renowned for its commitment to quality and patient care. The company’s core products include both prescription medications and over-the-counter solutions, distinguished by their efficacy and safety profiles. Recognised for its significant contributions to the pharmaceutical landscape, Eva Pharma has achieved numerous milestones, including partnerships with global organisations and a robust pipeline of new therapies. With a dedication to advancing healthcare, Eva Pharma continues to enhance its market position through innovation and excellence.
DitchCarbon Score
How does Eva Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Eva Pharma's score of 20 is lower than 84% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Eva Pharma's reported carbon emissions
Eva Pharma, headquartered in Egypt (EG), currently does not have specific carbon emissions data available for the most recent year, nor does it report any absolute emissions figures in kg CO2e. As a current subsidiary of a larger corporate family, it inherits its climate commitments and targets from its parent organization, Eva Pharma, but specific details regarding these commitments are not disclosed. The company has not outlined any reduction targets or initiatives, nor does it participate in recognised frameworks such as the Science Based Targets initiative (SBTi) or the Carbon Disclosure Project (CDP). Consequently, there are no significant achievements or milestones reported in terms of emissions reduction. In the absence of specific emissions data or reduction initiatives, it is essential to note that Eva Pharma's climate commitments remain vague, reflecting a broader industry context where many organisations are increasingly focusing on sustainability and carbon neutrality. However, without concrete data or targets, the company's current stance on climate action remains unclear.
How Carbon Intensive is Eva Pharma's Industry?
How Carbon Intensive is Eva Pharma's Location?
Eva Pharma's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Eva Pharma has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
